1. Home
  2. GGT vs NYXH Comparison

GGT vs NYXH Comparison

Compare GGT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Multi-Media Trust Inc. (The)

GGT

Gabelli Multi-Media Trust Inc. (The)

HOLD

Current Price

$4.10

Market Cap

176.4M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.45

Market Cap

161.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGT
NYXH
Founded
1994
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.4M
161.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GGT
NYXH
Price
$4.10
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
350.9K
181.6K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
15.56%
N/A
EPS Growth
N/A
N/A
EPS
0.83
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$213.98
Revenue Next Year
N/A
$126.25
P/E Ratio
$4.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.87
$1.26
52 Week High
$4.39
$8.59

Technical Indicators

Market Signals
Indicator
GGT
NYXH
Relative Strength Index (RSI) 49.47 N/A
Support Level $4.11 N/A
Resistance Level $4.26 N/A
Average True Range (ATR) 0.05 0.00
MACD 0.00 0.00
Stochastic Oscillator 42.90 0.00

Price Performance

Historical Comparison
GGT
NYXH

About GGT Gabelli Multi-Media Trust Inc. (The)

Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: